| abstract |
This disclosure relates to compositions and methods for treatment of minimal change disease. The compositions include soluble CTLA-4 molecules, and derivatives thereof, including belatacept and belatacept-like molecules that have been conjugated to a human immunoglobulin constant domain fragment. |